or Try an Advanced Search...

    Technical Analysis for ANVS - Annovis Bio, Inc.

    Grade Last Price % Change Price Change
    C 9.09 -2.05% -0.19
    ANVS closed down 2.05 percent on Friday, November 1, 2024, on 60 percent of normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.
    Earnings due: Nov 6
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Flat Up Down
    Historical ANVS trend table...
    Date Alert Name Type % Chg
    Fell Below 200 DMA Bearish 0.00%
    20 DMA Support Bullish 0.00%
    Wide Bands Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    200 DMA Support Bullish -2.05%
    Wide Bands Range Expansion -2.05%
    NR7 Range Contraction -4.82%
    Wide Bands Range Expansion -4.82%
    Gapped Down Weakness -4.82%
    Multiple of Ten Bearish Other -6.77%
    Older End-of-Day Signals for ANVS ...

       Recent Intraday Alerts

    Alert Time
    20 DMA Support about 20 hours ago
    Fell Below 20 DMA about 21 hours ago
    Down 3% about 21 hours ago
    Fell Below Previous Day's Low about 21 hours ago
    Down 2 % about 21 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    ANVS Chart by TradingView
    Basic chart:

    Profile

    Annovis Bio, Inc. develops drugs for Alzheimer's and Parkinson's diseases and other neurodegenerative disorders. It offers posiphen compound for mild cognitive impairment and early stage Alzheimer's disease and bisnorcymserine compound that inhibits amyloid formation and prevents the progression of the Alzheimer's disease. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Organ Systems Alzheimer's Disease Parkinson's Disease Psychiatric Diagnosis Amyloid Nervous System Neurodegeneration Neurodegenerative Disorders Cognitive Disorders Cognitive Impairment Learning Disabilities Neuroprotection Early Stage Alzheimer's Disease Gladstone Institutes

    Is ANVS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 31 IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio
    Oct 22 Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024
    Oct 17 Annovis Bio: Funding May Be An Issue For Announced Phase 3 Trials
    Oct 17 Annovis Bio To Continue Alzheimer's Disease Clinical Trials
    Oct 17 Annovis Bio Shows Promise on FDA Clearance for Alzheimer's Drug
    Oct 15 Annovis Bio up 5% as FDA clears phase 3 buntanetap program for Alzheimer's
    Oct 15 FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs
    Oct 3 Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases
    Oct 2 Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations
    Sep 30 Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra
    See more ANVS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 22.49
    52 Week Low 4.53
    Average Volume 237,903
    200-Day Moving Average 9.12
    50-Day Moving Average 8.62
    20-Day Moving Average 8.90
    10-Day Moving Average 9.50
    Average True Range 0.71
    RSI (14) 51.69
    ADX 18.13
    +DI 20.92
    -DI 18.02
    Chandelier Exit (Long, 3 ATRs) 8.42
    Chandelier Exit (Short, 3 ATRs) 9.16
    Upper Bollinger Bands 10.36
    Lower Bollinger Band 7.44
    Percent B (%b) 0.56
    BandWidth 32.89
    MACD Line 0.29
    MACD Signal Line 0.27
    MACD Histogram 0.0228
    Fundamentals Value
    Market Cap 96.17 Million
    Num Shares 10.6 Million
    EPS -4.84
    Price-to-Earnings (P/E) Ratio -1.88
    Price-to-Sales 0.00
    Price-to-Book 17.40
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 10.11
    Resistance 3 (R3) 10.14 9.83 9.94
    Resistance 2 (R2) 9.83 9.57 9.82 9.88
    Resistance 1 (R1) 9.46 9.41 9.31 9.43 9.82
    Pivot Point 9.16 9.16 9.08 9.14 9.16
    Support 1 (S1) 8.78 8.90 8.63 8.75 8.36
    Support 2 (S2) 8.48 8.74 8.46 8.30
    Support 3 (S3) 8.11 8.48 8.24
    Support 4 (S4) 8.07